Relmada appoints Paul Kelly as COO; amends NEO employment agreements, suspends retention payments

RELMADA THERAPEUTICS, INC.

Paul Kelly named COO effective Jan 1, 2025; salary $476K, target bonus 40%, severance 6 months.
Amended employment agreements for CEO Traversa, CFO Shenouda, CAO Ence extend option exercisability upon termination.
NEOs receive no salary increases for FY2025, no cash bonuses or long-term incentive awards for FY2024.
All further retention payments for NEOs and Kelly suspended until Board approves strategic initiatives.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul Kelly

Chief Operating Officer

RLMD · RELMADA THERAPEUTICS, INC.

Effective: 2025-01-01
Filed: January 6, 2025, 6:59 PM ET

Paul Kelly was elected by the Board of Directors (the “Board”) to the position of Chief Operating Officer of Relmada Therapeutics, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Kelly was elected as Chief Operating Officer at RELMADA THERAPEUTICS, INC..

Action: elected
Role: Chief Operating Officer

Exact text from the filing

Paul Kelly was elected by the Board of Directors (the “Board”) to the position of Chief Operating Officer of Relmada Therapeutics, Inc. (the “Company”).

View on SEC.gov

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-001249

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.